BLUEJET · NSE
Blue Jet Healthcare Limited
₹575.25
+1.24% (+₹7.05)
Prev. close
₹568.2
Volume
2,07,881
Delivery %
56.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Blue Jet Healthcare Limited
Blue Jet Healthcare Limited engages in the manufacturing and sale of artificial sweeteners, pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in products. It provides contrast media intermediates, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related supplies to healthcare, pharma, animal feed, and food and beverages industries. It has operations in India, Norway, France, the United States, Denmark, Thailand, Spain, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Akshay Bansarilal Arora
Headquarters
Thane
Employees
581
Website
bluejethealthcare.comExchange
View on NSE ↗Key stats
Market cap
₹9,978.60 Cr
P/E ratio (TTM)
42.5
Dividend yield
0.21%
EPS (TTM)
₹13.52
Beta (1Y · daily vs NIFTY 50)
1.68
Shares float
4.49 Cr
EPS · quarter ended Jun 2026
₹4.51
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹720.53 Cr | ₹711.60 Cr | ₹1,029.99 Cr | ₹947.32 Cr | |
| EBITDA | ₹243.04 Cr | ₹248.35 Cr | ₹423.99 Cr | ₹362.75 Cr |
| ₹160.03 Cr | ₹163.74 Cr | ₹305.20 Cr | ₹247.82 Cr | |
| Diluted EPS | ₹9.23 | ₹9.44 | ₹17.59 | ₹14.29 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| — | — | — | ₹862.07 Cr | ₹1,058.85 Cr | ₹1,417.53 Cr | ₹1,641.16 Cr | |
| — | — | — | ₹3.44 Cr | ₹1.61 Cr | ₹19.99 Cr | ₹42.18 Cr | |
| Stockholders' equity | — | — | — | ₹681.49 Cr | ₹845.22 Cr | ₹1,133.11 Cr | ₹1,359.91 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹141.56 Cr | ₹241.26 Cr | ₹45.77 Cr | ₹334.15 Cr | |
| Investing cash flow | — | ₹-147.25 Cr | ₹-263.76 Cr | ₹-35.18 Cr | ₹-275.58 Cr |
| — | ₹-4.24 Cr | ₹-1.99 Cr | ₹-18.56 Cr | ₹-30.69 Cr | |
| Capital expenditure | — | ₹-59.27 Cr | ₹-172.86 Cr | ₹-79.88 Cr | ₹-219.46 Cr |
| End cash position | — | ₹65.44 Cr | ₹40.95 Cr | ₹32.98 Cr | ₹60.86 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Oct 23–Jun 25(8Q) | Sep 25–Jun 26(4Q) | Jul 26 |
|---|---|---|---|
| Promoter | 86.00% | 79.81% | 73.15% |
| Public | 14.00% | 20.19% | 26.85% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Blue Jet Healthcare Limited | ₹9,801.66 Cr | ₹568.2 | 41.7 | 7.21 | 18.2% | 0.03 | -8.0% | -18.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
18 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.